trial

The Effect of JNJ-39393406 on Event Related Potentials in Stable Schizophrenic Patients

NCTId NCT01137799
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Terminated
Enrollment 47 (actual)
Sponsored by Janssen, L.P. - Investigator Initiated Studies Program
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Terminated
Enrollment
47 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Quadruple
Start
2009-08
Primary completion
—
Eligibility
MALE · 18 Years · 55 Years

Interventions & indications

Drugs
JNJ-39393406

Sponsors

Janssen, L.P. - Investigator Initiated Studies ProgramLead Sponsor

Sites

0 total

Facts & assertions

3 sourced
Enrollment
47
Phase
PHASE1
Status
TERMINATED
relationships
The graph out of here
drug
JNJ-39393406
drug
lead_sponsor
Janssen, L.P. - Investigator Initiated Studies Program
company
indication
Alzheimer's Disease
indication
Schizophrenia
indication
Alzheimer Disease
indication